Find an Alzheimer's clinical trial

If you are thinking about joining a trial

A listing here is a record that a study was registered. It is not a recommendation, and it does not mean the study is still recruiting or that anyone is eligible. Registry entries go stale.

Talk to the treating doctor first, then contact the study team listed on the official ClinicalTrials.gov record. The NIA's free referral line can help you look: 1-800-438-4380, weekdays, English and Spanish.

Search title, drug, condition or sponsor

Recruiting

Exact registry status

Phase

Intervention class

Study type

Country

Results per page

Clear filters Download all 7,816 as CSV

"Open to new participants" means the registry status is RECRUITING or NOT_YET_RECRUITING — 1,523 of the 7,816 records. That is what the sponsor last told the registry, which can be months out of date.
Location is by country. This pull of the registry records the countries a study runs in, not its individual sites, so we cannot filter by US state or city — and we are not going to guess one. To find the nearest site, open a trial's record below: the official page lists every location with its contact details.

Showing 2,526–2,550 of 7,816 matching trials · page 102 of 313, 25 per page.

Sorted by the date the registry record was last updated, newest first. This page never loads all 7,816 rows at once — use the CSV download if you want the whole file.

Registered Alzheimer's clinical trials. Every ID links to its official ClinicalTrials.gov record.
Trial	Phase	Status	Enrolled	Sponsor	Last updated
Obstructive Sleep Apnea and Biomarkers of Alzheimer's Disease NCT04905238 Continuous positive airway pressure Runs in: Spain · 2 sites	NA other	ENROLLING_BY_INVITATION	130	Alberto Alonso Fernandez OTHER_GOV	2025-05-01
Deep Brain Stimulation of the Pedunculopontine Nucleus for Alzheimer's Disease NCT06936124 Deep Brain Stimulation of the Pedunculopontine Nucleus Runs in: Canada · 1 site	NA other	RECRUITING	6	University Health Network, Toronto OTHER	2025-05-01
Exploratory Study of the Effects of Peptide PMS-001 on Long-Delay Recall in Patients With Moderate to Severe Dementia NCT06946511 Peptide PMS-001 Intravenous Injection; Placebo Runs in: China · 2 sites	PHASE1\|PHASE2 other	NOT_YET_RECRUITING	50	Ruijin Hospital OTHER	2025-05-01
Early-onset Alzheimer's Disease Phenotypes: Neuropsychology and Neural Networks NCT03153371 Runs in: United States · 1 site	NA other	COMPLETED	180	University of California, Los Angeles OTHER	2025-04-30
Effect of Physiologic Insulin Administration on Cognition NCT06424652 Blood draws; Hyperinsulinemic Euglycemic Clamp Technique Insulin Se... Runs in: United States · 1 site	NA other	COMPLETED	1	Pennington Biomedical Research Center OTHER	2025-04-30
A Prospective, Monocentric Clinical Study for the Validation of in Vitro Diagnostic Tests Developed by Firalis NCT06432192 APO-Easy Runs in: France · 2 sites	NA other	COMPLETED	1,474	Firalis SA INDUSTRY	2025-04-30
VR-Based Intervention for Caregiving Competence in Dementia NCT06797180 Virtual Reality Education for Dementia Caregivers Runs in: Taiwan · 1 site	NA other	ENROLLING_BY_INVITATION	120	Mackay Medical College OTHER	2025-04-30
A Safety and Tolerability Study of JNJ-54861911 in Participants With Early Alzheimer's Disease NCT02260674 JNJ-54861911, 10 milligram (mg); JNJ-54861911, 50 mg; Placebo Runs in: Belgium; France; Germany; Netherlands; Spain; Sweden · 19 sites	PHASE2 other	COMPLETED	114	Janssen Research & Development, LLC INDUSTRY	2025-04-29
An Extension Study to Evaluate the Long-Term Safety and Tolerability of JNJ-54861911 in Participants in the Early Alzheimer's Disease Spectrum NCT02406027 JNJ-54861911, 10 mg; JNJ-54861911, 25 mg; Placebo; JNJ-54861911, 5 mg Runs in: Belgium; France; Germany; Netherlands; Spain; Sweden · 17 sites	PHASE2 other	TERMINATED	90	Janssen Research & Development, LLC INDUSTRY	2025-04-29
An Efficacy and Safety Study of Atabecestat in Participants Who Are Asymptomatic at Risk for Developing Alzheimer's Dementia NCT02569398 Atabecestat, 5 mg; Atabecestat, 25 mg; Placebo Runs in: Australia; Belgium; Canada; Denmark; Finland; Germany; Ja... · 128 sites	PHASE2\|PHASE3 BACE-inhibitor	TERMINATED	557	Janssen Research & Development, LLC INDUSTRY	2025-04-29
Epigenetic Biomarkers for Alzheimer's Disease NCT04081285 Runs in: Hong Kong · 1 site	NA other	COMPLETED	250	Chinese University of Hong Kong OTHER	2025-04-29
All About Me: An Intervention to Ease the Transition to Long Term Care NCT05516134 SAFE at Home Runs in: United States · 1 site	NA other	COMPLETED	51	Hopeful Aging INDUSTRY	2025-04-29
A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD NCT05686044 Buntanetap/Posiphen; Placebo Runs in: United States · 54 sites	PHASE2\|PHASE3 other	COMPLETED	351	Annovis Bio Inc. INDUSTRY	2025-04-29
Five Lives MED to Improve Cognitive Function in Mild Cognitive Impairment NCT06598163 Five Lives MED Runs in: France; United Kingdom · 7 sites	NA other	RECRUITING	170	SharpTx INDUSTRY	2025-04-29
AI-Enhanced Optimization of Acute Levodopa Challenge Test NCT06949865 video recording Runs in: China · 1 site	NA other	RECRUITING	2,000	Beijing Tiantan Hospital OTHER	2025-04-29
The Swedish BioFINDER Study NCT01208675 Runs in: Sweden · 2 sites	NA other	COMPLETED	1,150	Skane University Hospital OTHER	2025-04-27
A Study to Investigate the Regional Brain Kinetics of Brain Drug Transporters Using P-glycoprotein and Breast Cancer Resistance Protein Substrates and by Using the Positron Emission Tomography Ligand 11C-JNJ-63779586 in the Human Brain NCT03089918 11C-JNJ-63779586 Runs in: Belgium · 2 sites	PHASE1 other	COMPLETED	11	Janssen Research & Development, LLC INDUSTRY	2025-04-27
Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants NCT03239561 [18F]MNI-1020 Runs in: United States · 1 site	EARLY_PHASE1 other	COMPLETED	15	Janssen Research & Development, LLC INDUSTRY	2025-04-27
A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-63733657 in Healthy Subjects and Subjects With Alzheimer's Disease NCT03375697 JNJ-63733657; Placebo Runs in: Belgium; Germany; Netherlands; Spain · 7 sites	PHASE1 other	COMPLETED	72	Janssen Research & Development, LLC INDUSTRY	2025-04-27
Characterization of T-Cell Response in Participants Previously Treated With JNJ-54861911 (Atabecestat) NCT03587376 Atabecestat Runs in: Belgium; France; Germany; Spain; Sweden · 5 sites	EARLY_PHASE1 BACE-inhibitor	COMPLETED	9	Janssen Research & Development, LLC INDUSTRY	2025-04-27
A Study of Comparing Rates of Dementia and Alzheimer's Disease in Participants Initiating Methotrexate Versus Those Initiating Anti-tumor Necrosis Factor (TNF)-Alpha Therapy NCT04571697 Methotrexate; Anti-TNF Runs in: United States · 1 site	NA other	COMPLETED	34,647	Janssen Research & Development, LLC INDUSTRY	2025-04-27
A Study of Seltorexant in Participants With Probable Alzheimer's Disease NCT05307692 Seltorexant; Placebo Runs in: United States · 25 sites	PHASE2 other	COMPLETED	88	Janssen Research & Development, LLC INDUSTRY	2025-04-27
Histidine Oral Supplementation as a Therapeutic Modality for Alzheimer's Disease NCT06169826 l-Histidine; Control Runs in: United States · 1 site	PHASE4 other	WITHDRAWN	0	Wake Forest University Health Sciences OTHER	2025-04-27
Cognitive Health in Ageing Register: Investigational, Observational and Trial Studies in Dementia Research: Prospective Readiness Cohort Study NCT02114372 Runs in: United Kingdom · 2 sites	NA other	COMPLETED	1,136	Janssen Research & Development, LLC INDUSTRY	2025-04-25
The Combined Aerobic Exercise and Cognitive Training (ACT) Trial: The ACT Trial NCT03313895 Aerobic & Cognitive Training (ACT); Cycling Only; Cognitive Trainin... Runs in: United States · 4 sites	NA other	COMPLETED	146	Arizona State University OTHER	2025-04-25

This table is wider than a phone screen — swipe it sideways to see the rest.

Where these trials come from

Registry: ClinicalTrials.gov, pulled through their public API (v2)
Trials in the file: 7,816
Source file: trials.csv (3.8 MB, 7816 rows)
Basis: Measured These are registry records as submitted by each study's sponsor.

What could make this misleading

Sponsors enter their own data and do not always keep it current, so "recruiting" can be out of date by months or years. Enrollment figures may be targets rather than actual numbers; the downloaded file says which for each trial. Trials that were never registered do not appear at all, and the intervention class is this project's own grouping, not the registry's.

Always check the official record before acting on anything here. This is a summary, not medical advice.

From the research library

The highest-scoring studies we hold on this subject, each summarised in plain English. Scores are alzhub's usefulness score, not a verdict on the science.

Clinical trials

MINocyclinE to Reduce inflammation and blood-brain barrier leakage in small Vessel diseAse (MINERVA): A phase II, randomized, double-blind, placebo-controlled experimental medicine trial Alzheimer's & dementia : the journal of the Alzheimer's Association, 2024 · score 88/100
Safety and efficacy of crenezumab in cognitively unimpaired carriers of the PSEN1Glu280Ala mutation at risk for autosomal-dominant Alzheimer's disease in Colombia (API ADAD Colombia Trial): a phase 2, randomised, double-blind, placebo-controlled trial The Lancet. Neurology, 2026 · score 86/100
Study of mirtazapine for agitated behaviours in dementia (SYMBAD): a randomised, double-blind, placebo-controlled trial Lancet (London, England), 2021 · score 86/100
Randomized, double-blind study of zervimesine in mild to moderate Alzheimer's disease Journal of Alzheimer's disease : JAD, 2026 · score 86/100
Efficacy assessment of an active tau immunotherapy in Alzheimer's disease patients with amyloid and tau pathology: a post hoc analysis of the "ADAMANT" randomised, placebo-controlled, double-blind, multi-centre, phase 2 clinical trial EBioMedicine, 2024 · score 85/100

All 162 studies on Clinical trials →